We were delighted to speak to Dr Anna van der Voort, The Netherlands Cancer Institute, to discuss her presentation at the ASCO20 Virtual Scientific Program on the long-term follow-up data of the randomised, multicentre, open-label phase III TRAIN-2 trial (ClinicalTrials.gov Identifier: NCT01996267).
Questions
1. What are the major unmet needs in current neoadjuvant chemotherapy regimes for women undergoing dual HER2 blockade for stage II–III HER2-positive breast cancer? (0:06)
2. Could you give us a brief overview of the TRAIN-2 study and its major findings? (1:08)
3. What have the long-term findings of this study taught us about the use of anthracyclines? (4:56)
4. What questions will the TRAIN-3 study address? (5:48)
5. What other approaches should be investigated in this treatment setting? (7:10)
Speaker disclosure: Anna van der Voort has no financial or non-financial relationships or activities to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2020 ASCO Virtual Scientific Program.
